GlassScriptPhysician profile
Reshama Grover
NPI 1548213044
$3,915.12
in general payments reported to CMS, 2019-2025
37 companies · $919 in 2025
The $919 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $415 · 2022: $1,010 · 2023: $632 · 2024: $940 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,490.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $955.67 | 2021-2025 | Reblozyl, Onureg, Pomalyst |
| Incyte Corporation | $433.63 | 2021-2025 | Monjuvi, Jakafi, Jakafi |
| Janssen Scientific Affairs, LLC | $225.34 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $212.94 | 2021-2025 | Iclusig, Livtencity |
| Seagen INC. | $191.64 | 2021-2023 | Adcetris |
| Legend Biotech USA INC. | $170.70 | 2023-2025 | Carvykti |
| Amgen INC. | $160.48 | 2021-2024 | Blincyto |
| Pfizer INC. | $141.88 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $129.86 | 2022-2024 | |
| Janssen Biotech, INC. | $120.90 | 2024-2025 | Carvykti, Talvey, Darzalex |
| Karyopharm Therapeutics INC. | $115.02 | 2022-2025 | Xpovio |
| Abbvie INC. | $102.80 | 2024-2025 | |
| Adc Therapeutics America, INC. | $99.95 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $75.51 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $60.91 | 2024-2025 | Prevymis |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $59.37 | 2023-2025 | Yescarta |
| Sanofi-Aventis U.S. LLC | $56.84 | 2022-2024 | |
| Epizyme, INC. | $52.14 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $51.91 | 2022-2023 | Nuzyra |
| Sobi, INC | $51.90 | 2024 | |
| Servier Pharmaceuticals LLC | $51.59 | 2021-2025 | |
| Morphosys, US INC. | $51.57 | 2022-2023 | Monjuvi |
| Syndax Pharmaceuticals, INC. | $42.11 | 2025 | |
| Genmab U.S., INC. | $30.93 | 2025 | Epkinly |
| Blueprint Medicines Corporation | $27.44 | 2023 | Ayvakit |
| Daiichi Sankyo INC. | $26.26 | 2025 | Vanflyta |
| Beone Medicines USA, INC. | $24.68 | 2025 | Brukinsa |
| Coherus Oncology, INC. | $24.60 | 2023 | |
| Biolinerx USA, INC. | $22.16 | 2024 | Aphexda |
| Lilly USA, LLC | $21.59 | 2024 | Jaypirca |
| Genzyme Corporation | $19.83 | 2024 | |
| Genentech USA, INC. | $19.34 | 2025 | Venclexta |
| Acrotech Biopharma INC. | $18.97 | 2024 | Beleodaq |
| Glaxosmithkline, LLC. | $18.25 | 2024 | Ojjaara |
| Beigene USA, INC. | $15.83 | 2021 | |
| Astellas Pharma US INC | $15.56 | 2025 | Cresemba |
| Stemline Therapeutics INC. | $15.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshama Grover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.